ClinicalTrials.gg
RecruitingNCT06944743Updated Apr 25, 2025

TURP Inpatient With Underactive Bladder With BOO

An interventional study of Transurtheral Resection of prostate ( TURP) in TURP Syndrome, Retention, Urinary and Prostate Disease, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to male participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-25.

Sponsored by Sohag University · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
40 Years to 70 Years
Sex
Male
01

Study summary

The study is for aproved that Transurtheral Resection of prostate is good for patient with underactive bladder or not.

Read the detailed description

Introduction:

Aging men frequently develop lower urinary tract symptoms (LUTS). These symptoms are commonly attributed to bladder outlet obstruction by benign prostatic hyperplasia (BPH) and the clinical condition is termed BPH. However, recent studies have implicated many factors in the pathogenesis of LUTS in addition to BPH. These include prostate inflammation and fibrosis, increased serum estrogen/testosterone ratio, diabetes, the metabolic syndrome, sleep apnea, polyuria and changes in bladder function .

Transurethral resection of prostate (TURP) is a time-tested gold standard surgical option for dealing with LUTS in men having benign prostatic enlargement (BPE) . Persistence of LUTS is reported in 5%-35% of patients undergoing TURP .

Detrusor Under activity (DUA) is defined by the International Continence Society (ICS) as "a contraction of reduced strength and/or duration, resulting in prolonged bladder emptying and/or failure to achieve complete bladder emptying within a normal time span" . Detrusor underactivity was demonstrated in 17% men presenting with LUTS after urodynamic evaluation .

Male DUA definition remains controversial and no effective treatment is consolidated. The role of prostatic surgery in male DUA is not clear. The primary endpoint was the clinical and voiding improvement based on International Prostate Symptom Score (IPSS) and the maximum flow rate in uroflowmetry (Qmax) within 12 months.

DUA is a common association for persistence of symptoms after TURP in such patients .

Projected isovolumetric pressure (PIP) was proposed by Schäfer, who used a straight line to represent the Bladder Outlet Relation (BOR) and then "projected" back to the y-axis (pdet) from the point representing pdet@Qmax to obtain the isovolumetric pressure. This projection is calculated by the formula PIP = Pdet@Qmax + KQmax where K is a fixed constant representing the steepness of the angle of the BOR to x-a axis .

K is dependent on the specific population studied and differs between men and women .In men it is usually taken as 5. The suggested groupings for PIP are as follows:

  • >150 - strong contractility
  • 100 to 150 - normal contractility
  • 50 to 100 - weak contractility
  • \<50 - very weak contractility Surgical failure is more likely to occur in patients with detrusor dysfunction and lower baseline Bladder outlet obstruction index (BOOI ). It has also been found that the degree of preoperative BOO is positively associated with improvement and QoL after TURP . Therefore, a preoperative Pressure Flow Study (PFS) is recommended for optimal selection of patients who are more suitable for surgery by measuring BOOI and assessing detrusor function. BOOI (PdetQmax-2Qmax) .

Conflicting results create dilemma about the efficacy and results of TURP in patients with BPE and bladder underactivity . In this study, Investigators evaluate the Predictors of Improvement after Transurethral Resection of Prostate in Patients with Underactive Bladder and Bladder outlet obstruction.

Aim of the work:

To pick up the predictors of improvement after Transurethral Resection of Prostate in Patients with Underactive Bladder and Bladder outlet obstruction.

Pre-Operative Predictors:

  1. Age.
  2. Body mass index.
  3. pre-operative urinary flow rate.
  4. International Prostate Symptom Score (IPSS).
  5. Urodynamic parameters (BCI, BOOI, PVR and bladder capacity.........etc.).
  6. Prostate size.
  7. Degree of vesicoureteral reflux (if present).
  8. Functional Bladder Capacity.

Intra-Operative Predictors:

  1. Surgical technique.
  2. Prostatic Resected weight.
  3. Intra-operative complications.
  4. Prostate type (Bilobular,trilobular,adenomatous or fibrous).
  5. TURP syndrome.

Post-Operative Predictors:

  1. Catheterization duration.
  2. post-operative urinary retention.
  3. Complications: (e.g., infections, stricture).
  4. Early post-operative voiding trials.
  5. Measure degree of vesicoureteral reflux after TURP.
  6. Functional bladder Capacity after TURP.

Urodynamic Predictors:

  1. Detrusor contractility.
  2. Bladder outlet obstruction.
  3. Functional bladder capacity.
  4. UAB severity: Mild/moderate (UAB symptoms).
  5. Maximum urinary flow rate.
  6. Compliance of bladder.

Other Predictors:

  1. Patient expectations: Realistic expectations and mental health influence.
  2. Co-morbidities.
  3. pre-operative physical therapy.
  4. Smoking cessation.

Surgical Technique:

Perioperative antibiotic coverage for surgery should be carefully considered especially for patient who has an indwelling catheter (urethral or suprapubic).

TURP is performed using spinal anesthesia. TURP involves an endoscopic approach via the patient's urethra to surgically remove the inner portion of the prostate that encircles the urethra. A bipolar electrified wire loop is used to remove the portion of the prostate between the bladder neck and the verumontanum to a depth of the surgical capsule. Before the resection is begun, the bladder should be inspected for any bladder pathology (e.g., tumor, diverticula or stones).

The bladder neck, trigone, and position of the ureteral orifices, verumontanum, and external sphincter should be noted. Three-way Foley catheter is usually placed to and traction for a short time, release of traction based on clearance of hematuria.

In the absence of significant capsular perforation or persistent bleeding, the catheter can be removed after 24 to 48 hours.

.

02

Conditions studied

  • TURP Syndrome
  • Retention, Urinary
  • Prostate Disease
03

In context

Urinary Retention

241 studies on the registry are indexed under Urinary Retention; 44 are open to participants now.

This study's planned enrollment of 50 is below the median of 90 across 187 interventional studies indexed under Urinary Retention.

Browse Urinary Retention studies →

Lead sponsor

Sohag University is the lead sponsor of 1,230 studies on the registry; 636 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patients diagnosed with BOO and UAB
  • Age ≥ 40 years.

Exclusion criteria

Exclusion Criteria:

  • Patient insulin dependent diabetes
  • Patient with history of cerbrovascular stroke or hemarrage.
  • History of prior prostate surgery.
  • Urethral pathology or surgery.
  • Patient with prostate or bladder cancer.
  • Spinal and pelvic trauma or surgery.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Other
    Transurtheral Resection of prostate in underactive bladder with bladder outlet obstruction

    TURP involves an endoscopic approach via the patient's urethra to surgically remove the inner portion of the prostate that encircles the urethra. A bipolar electrified wire loop is used to remove the portion of the prostate between the bladder neck and the verumontanum to a depth of the surgical capsule. Before the resection is begun, the bladder should be inspected for any bladder pathology (e.g., tumor, diverticula or stones). The bladder neck, trigone, and position of the ureteral orifices, verumontanum, and external sphincter should be noted. Three-way Foley catheter is usually placed to and traction for a short time, release of traction based on clearance of hematuria.

    Procedure: Transurtheral Resection of prostate ( TURP)

Interventions

  • ProcedureTransurtheral Resection of prostate ( TURP)

    TURP involves an endoscopic approach via the patient's urethra to surgically remove the inner portion of the prostate that encircles the urethra. A bipolar electrified wire loop is used to remove the portion of the prostate between the bladder neck and the verumontanum to a depth of the surgical capsule. Before the resection is begun, the bladder should be inspected for any bladder pathology (e.g., tumor, diverticula or stones). The bladder neck, trigone, and position of the ureteral orifices, verumontanum, and external sphincter should be noted. Three-way Foley catheter is usually placed to and traction for a short time, release of traction based on clearance of hematuria.

06

What researchers measure

Primary outcomes

  1. Change in international prostate symptome score (IPSS) score.

    Outcome measure Detrusar pressure at maximum flow (Pdet-Qmax unit:CmH2O)

    Time frame: 3 month .

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06944743
Lead sponsor
Sohag University
Responsible party
Emad Abdellah Ali Mostafa (Director,Head of urology,Principal investigator,clinical professor, Sohag University) — Principal investigator
First posted
Apr 25, 2025
Start date
Apr 1, 2025
Primary completion
Apr 1, 2026 (estimated)
Completion
Apr 1, 2026 (estimated)
Last update
Apr 25, 2025

Study contacts

Emad Mostafa, MD
Contact
emad_mostafa@med.sohag.edu.eg
01092590078
Emad Mostafa, MD
principal investigator · Assistant lecture

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion